---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-016633"
form_type: "8-K"
ticker: "FULC"
cik: "0001680581"
company_name: "Fulcrum Therapeutics, Inc."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T00:55:13.951461+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Fulcrum Therapeutics Q2 net loss $34.1M; cuts 18 jobs, saves $40-50M, cash into mid-2024

## Summary
- Net loss $34.1M ($0.65 per share) vs $19.6M in Q2 2021; cash $169M as of June 30.
- Workforce reduction of 18 positions (~25% of planned headcount) primarily in discovery, research, and G&A.
- Expects ~$40-50M operating expense savings fully realized by mid-2024; cash runway extended into mid-2024.
- Phase 1b data for FTX-6058 in SCD showed HbF increases up to 6.3%; first patient enrolled in Phase 3 REACH trial for losmapimod in FSHD.
- Promoted Mel Hayes to COO and Curt Oltmans to Chief Legal Officer.

## SEC filing metadata
- accession: 0000950170-22-016633
- form_type: 8-K
- ticker: FULC
- cik: 0001680581
- company_name: Fulcrum Therapeutics, Inc.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680581/000095017022016633/0000950170-22-016633-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680581/000095017022016633/fulc-20220811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-016633
- JSON: https://secwatch.observer/filing/0000950170-22-016633.json
- Plain text: https://secwatch.observer/filing/0000950170-22-016633.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.